Tuna Mutis

13.3k citations

180 papers · 9.4k · 2 hit papers · h-index 50

Impact in

Hematology top 0.1%
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
Immunology top 0.2%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology

Papers in

Immunology 101
- Immune Cell Function and Interaction 60
- Immunotherapy and Immune Responses 53
- T-cell and B-cell Immunology 41
Oncology 84
- CAR-T cell therapy research 54
- Peptidase Inhibition and Analysis 18

Co-authors: Niels W.C.J. van de Donk (60 shared papers)Els Goulmy (28 shared papers)Henk M. Lokhorst (49 shared papers)Paul W.H.I. Parren (22 shared papers)Richard W.J. Groen (32 shared papers)Sonja Zweegman (43 shared papers)Ellen Schrama (11 shared papers)Tom H. M. Ottenhoff (7 shared papers)
Journals: Blood (58 papers)Clinical Cancer Research (13 papers)The Journal of Immunology (7 papers)Haematologica (7 papers)HemaSphere (7 papers)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Tuna Mutis

174 papers receiving 9.2k citations

Tuna Mutis's Hit Papers

align trajectories log scale

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma 2016 · 649 citations

Peers

Countries citing papers authored by Tuna Mutis

Since Specialization

Citations

This map shows the geographic impact of Tuna Mutis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tuna Mutis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tuna Mutis more than expected).

Fields of papers citing papers by Tuna Mutis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tuna Mutis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tuna Mutis. The network helps show where Tuna Mutis may publish in the future.

Co-authors

The 25 scholars most cited alongside Tuna Mutis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tuna Mutis Line = papers co-authored together Tuna Mutis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 180 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors The Journal of Immunology ·Michel de Weers, Yu‐Tzu Tai, Michael S. van der Veer, Joost M. Bakker, Tom Vink, Daniëlle C.H. Jacobs, Lukas A. Oomen, Matthias Peipp, Thomas Valerius, Jerry W. Slootstra, Tuna Mutis, Wim K. Bleeker, Kenneth C. Anderson, Henk M. Lokhorst, Jan G. J. van de Winkel, Paul W.H.I. Parren Hit paper breakdown →	2010	746
2	Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma Blood ·Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, Khaja Syed, Kevin Liu, Niels W.C.J. van de Donk, Brendan M. Weiss, Tahamtan Ahmadi, Henk M. Lokhorst, Tuna Mutis, A. Kate Sasser Hit paper breakdown →	2016	649
3	Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma mAbs ·Marije B. Overdijk, Sandra Verploegen, Marijn Bögels, Marjolein van Egmond, Jeroen J. Lammerts van Bueren, Tuna Mutis, Richard W.J. Groen, Esther C.W. Breij, Anton C. Martens, Wim K. Bleeker, Paul W.H.I. Parren	2015	370
4	Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia Proceedings of the National Academy of Sciences ·W. A. Erik Marijt, Mirjam H.M. Heemskerk, Freke M. Kloosterboer, Els Goulmy, Michel G.D. Kester, Menno A. W. G. van der Hoorn, Simone A. P. van Luxemburg-Heys, Manja Hoogeboom, Tuna Mutis, Jan W. Drijfhout, Jon J. van Rood, Roel Willemze, J.H. Frederik Falkenburg	2003	325
5	Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization Blood ·Jorg van Loosdregt, Yvonne Vercoulen, Teun Guichelaar, Yoony Y. J. Gent, Jeffrey M. Beekman, Olivier van Beekum, Arjan B. Brenkman, DirkJan Hijnen, Tuna Mutis, Eric Kalkhoven, Berent J. Prakken, Paul J. Coffer	2009	311
6	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma Blood ·Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen, Berris van Kessel, Amy Axel, Khaja Syed, Richard W.J. Groen, Mark van Duin, Pieter Sonneveld, Monique C. Minnema, Sonja Zweegman, Christopher Chiu, Andries C. Bloem, Tuna Mutis, Henk M. Lokhorst, A. Kate Sasser, Niels W.C.J. van de Donk	2016	275
7	Feasibility of Immunotherapy of Relapsed Leukemia With Ex Vivo–Generated Cytotoxic T Lymphocytes Specific for Hematopoietic System-Restricted Minor Histocompatibility Antigens Blood ·Tuna Mutis, Robert M. Verdijk, Ellen Schrama, Bennie Esendam, Anneke Brand, Els Goulmy	1999	241
8	In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens Nature Medicine ·Anne M. Dickinson, Xiao-Nong Wang, Lisbet Sviland, Florry A. Vyth‐Dreese, Graham Jackson, Ton N. Schumacher, John B.A.G. Haanen, Tuna Mutis, Els Goulmy	2002	239
9	Polyriboinosinic Polyribocytidylic Acid (Poly(I:C)) Induces Stable Maturation of Functionally Active Human Dendritic Cells The Journal of Immunology ·Robert M. Verdijk, Tuna Mutis, Ben Esendam, Janine Kamp, Cees J. M. Melief, Anneke Brand, Els Goulmy	1999	237
10	Monoclonal antibodies targeting CD38 in hematological malignancies and beyond Immunological Reviews ·Niels W.C.J. van de Donk, Maarten L. Janmaat, Tuna Mutis, Jeroen J. Lammerts van Bueren, Tahamtan Ahmadi, A. Kate Sasser, Henk M. Lokhorst, Paul W.H.I. Parren	2016	237
11	A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization Molecular Therapy ·Esther Drent, Maria Themeli, Renée Poels, Regina de Jong-Korlaar, Huipin Yuan, Joost D. de Bruijn, Anton C. Martens, Sonja Zweegman, Niels W.C.J. van de Donk, Richard W.J. Groen, Henk M. Lokhorst, Tuna Mutis	2017	216
12	Tetrameric HLA class I–minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease Nature Medicine ·Tuna Mutis, Geraldine M. Gillespie, Ellen Schrama, J.H. Frederik Falkenburg, Paul Moss, Els Goulmy	1999	215
13	Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab Leukemia ·Inger S. Nijhof, Richard W.J. Groen, H M Lokhorst, Berris van Kessel, A C Bloem, Jeroen van Velzen, Regina de Jong-Korlaar, Huipin Yuan, Willy A. Noort, Saskia K. Klein, Anton C. Martens, Parul Doshi, K. Sasser, Tuna Mutis, Niels W.C.J. van de Donk	2015	203
14	Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin Proceedings of the National Academy of Sciences ·Yvonne van de Wal, Y Kooy, Peter A. van Veelen, Salvador A. Peña, Luisa Mearin, Øyvind Molberg, Knut E. A. Lundin, Ludvig M. Sollid, Tuna Mutis, Willemien E. Benckhuijsen, Jan W. Drijfhout, Frits Koning	1998	185
15	Pregnancy induces minor histocompatibility antigen–specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy Blood ·Robert M. Verdijk, Antoinette Kloosterman, Jos Pool, Maarten van de Keur, Albert Naipal, Astrid G. S. van Halteren, Anneke Brand, Tuna Mutis, Els Goulmy	2003	169
16	Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab Haematologica ·Michael S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, S. Wittebol, Paul W.H.I. Parren, HM Lokhorst, Tuna Mutis	2010	168
17	Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma Haematologica ·Esther Drent, Richard W.J. Groen, Willy A. Noort, Maria Themeli, Jeroen J. Lammerts van Bueren, Paul W.H.I. Parren, Jürgen Kuball, Zsolt Sebestyén, Huipin Yuan, Joost D. de Bruijn, Niels W.C.J. van de Donk, Anton C. Martens, HM Lokhorst, Tuna Mutis	2016	141
18	Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial Blood ·Evelien Kneppers, Bronno van der Holt, Marie José Kersten, Sonja Zweegman, Ellen Meijer, Gerwin Huls, Jan J. Cornelissen, Jeroen J. W. M. Janssen, Cynthia Huisman, Petra Cornelisse, Cheryl P. Bruijnen, Maarten E. Emmelot, Pieter Sonneveld, Henk M. Lokhorst, Tuna Mutis, Monique C. Minnema	2011	139
19	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells Clinical Cancer Research ·Esther Drent, Renée Poels, Ruud Ruiter, Niels W.C.J. van de Donk, Sonja Zweegman, Huipin Yuan, Joost D. de Bruijn, Michel Sadelain, Henk M. Lokhorst, Richard W.J. Groen, Tuna Mutis, Maria Themeli	2019	135
20	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Clinical Cancer Research ·Jakub Krejcik, Kris A. Frerichs, Inger S. Nijhof, Berris van Kessel, Jeroen F. van Velzen, Andries C. Bloem, Marloes E.C. Broekmans, Sonja Zweegman, Johan van Meerloo, René J.P. Musters, Pino J. Poddighe, Richard W.J. Groen, Christopher Chiu, Torben Plesner, Henk M. Lokhorst, A. Kate Sasser, Tuna Mutis, Niels W.C.J. van de Donk	2017	119

About Tuna Mutis

Tuna Mutis is a scholar working on Immunology, Oncology, Hematology, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 180 papers that have together received 9.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (66 papers), Immune Cell Function and Interaction (60 papers), CAR-T cell therapy research (54 papers), Immunotherapy and Immune Responses (53 papers), T-cell and B-cell Immunology (41 papers), Monoclonal and Polyclonal Antibodies Research (34 papers), Peptidase Inhibition and Analysis (18 papers) and Hematopoietic Stem Cell Transplantation (18 papers). The work is most often cited by research in Hematology (4.2k citations), Immunology (4.7k citations), Oncology (4.1k citations), Physiology (527 citations) and Genetics (822 citations). Tuna Mutis has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Niels W.C.J. van de Donk, Els Goulmy, Henk M. Lokhorst, Paul W.H.I. Parren, Richard W.J. Groen, Sonja Zweegman, Ellen Schrama, Tom H. M. Ottenhoff, Inger S. Nijhof and Anton C. Martens. Their work appears in journals such as Blood, Clinical Cancer Research, The Journal of Immunology, Haematologica and HemaSphere.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Tuna Mutis

Impact in

Papers in i

In The Last Decade

Tuna Mutis

Tuna Mutis's Hit Papers

Peers

Countries citing papers authored by Tuna Mutis

Fields of papers citing papers by Tuna Mutis

All Works

About Tuna Mutis

Explore authors with similar magnitude of impact

Papers in